PhaseBio Pharmaceuticals, Inc. Launches Clinical Program to Test Lead Product for Sustained 24/7 Glycemic Control in Type 2 Diabetics

Published: Dec 01, 2010

MALVERN, Pa.--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc., a privately held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, announced today that it has begun Phase 1/2a clinical testing with its lead compound, GlymeraTM (PB1023), in patients with Type 2 diabetes. GlymeraTM is a novel recombinant glucagon-like peptide-1 (GLP-1) analog which has been genetically engineered in a highly efficient, low-cost, Escherichia coli expression system using the company’s elastin-like biopolymer technology.

Back to news